Cite
Development and implementation of optimized endogenous contrast sequences for delineation in adaptive radiotherapy on a 1.5T MR-linear-accelerator: a prospective R-IDEAL stage 0-2a quantitative/qualitative evaluation of in vivo site-specific quality-assurance using a 3D T2 fat-suppressed platform for head and neck cancer
MLA
Neck Radiotherapy-MRI Development Cooperative, Joint Head and, et al. “Development and Implementation of Optimized Endogenous Contrast Sequences for Delineation in Adaptive Radiotherapy on a 1.5T MR-Linear-Accelerator: A Prospective R-IDEAL Stage 0-2a Quantitative/Qualitative Evaluation of in Vivo Site-Specific Quality-Assurance Using a 3D T2 Fat-Suppressed Platform for Head and Neck Cancer.” Journal of Medical Imaging, vol. 10, no. 6, Nov. 2023, p. 65501. EBSCOhost, https://doi.org/10.1117/1.JMI.10.6.065501.
APA
Neck Radiotherapy-MRI Development Cooperative, J. H. and, Salzillo, T. C., Dresner, M. A., Way, A., Wahid, K. A., McDonald, B. A., Mulder, S., Naser, M. A., He, R., Ding, Y., Yoder, A., Ahmed, S., Corrigan, K. L., Manzar, G. S., Andring, L., Pinnix, C., Stafford, R. J., Mohamed, A. S. R., Christodouleas, J., & Wang, J. (2023). Development and implementation of optimized endogenous contrast sequences for delineation in adaptive radiotherapy on a 1.5T MR-linear-accelerator: a prospective R-IDEAL stage 0-2a quantitative/qualitative evaluation of in vivo site-specific quality-assurance using a 3D T2 fat-suppressed platform for head and neck cancer. Journal of Medical Imaging, 10(6), 65501. https://doi.org/10.1117/1.JMI.10.6.065501
Chicago
Neck Radiotherapy-MRI Development Cooperative, Joint Head and, Travis C. Salzillo, M. Alex Dresner, Ashley Way, Kareem A. Wahid, Brigid A. McDonald, Sam Mulder, et al. 2023. “Development and Implementation of Optimized Endogenous Contrast Sequences for Delineation in Adaptive Radiotherapy on a 1.5T MR-Linear-Accelerator: A Prospective R-IDEAL Stage 0-2a Quantitative/Qualitative Evaluation of in Vivo Site-Specific Quality-Assurance Using a 3D T2 Fat-Suppressed Platform for Head and Neck Cancer.” Journal of Medical Imaging 10 (6): 65501. doi:10.1117/1.JMI.10.6.065501.